SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 6, 2012 (June 5, 2012)

 

 

Neuralstem, Inc.

(Exact name of registrant as specified in Charter)

 

 

Delaware   000-1357459  

52-2007292

 

(State or other jurisdiction of

incorporation or organization)

   (Commission File No.)   (IRS Employee Identification No.)

 

9700 Great Seneca Highway, Rockville, Maryland 20850

(Address of Principal Executive Offices)

 

(301) 366-4841

(Issuer Telephone number)

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

  

Item 8.01. Other Events.

 

On June 5, 2012, Neuralstem, Inc. (“Company”) announced that the Emory University Institutional Review Board (“IRB”) approved the amendment to the ongoing Phase I trial evaluating the Company’s spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). The amended protocol was approved earlier this year by the United States Food and Drug Administration subject to IRB approval. A copy of the press release is attached to this report as Exhibit 99.01.

 

Item 9.01     Financial Statement and Exhibits.

 

Exhibit Number

 

   Description  
     
99.01   Press Release Dated June 5, 2012

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Issuer has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  NEURALSTEM, INC
   
  By:  /s/ I. Richard Garr
    I. Richard Gaar
Chief Executive Officer

  

Dated: June 6, 2012